Patient and population impacts of multigene panel and pembrolizumab coverage in metastatic melanoma
The policy of reimbursing multigene testing and pembrolizumab produced patient survival improvements, but selectivity of response prevented population mortality improvement. Health-care system costs statistically significantly increased at the patient and population levels.
Authors
- H Anderson (ORCID: https://orcid.org/0000-0002-4666-3622)
- Melanie McPhail (ORCID: https://orcid.org/0000-0001-7156-5162)
- Deirdre Weymann (ORCID: https://orcid.org/0000-0002-3072-5657)
- Dean A. Regier (ORCID: https://orcid.org/0000-0001-8876-0511)
- Stephen Yip (ORCID: https://orcid.org/0000-0002-8514-9861)
- Michael R. Law (ORCID: https://orcid.org/0000-0002-5637-6053)
- Alison M. Weppler (ORCID: https://orcid.org/0000-0003-3769-490X)
- Samantha Pollard (ORCID: https://orcid.org/0000-0002-3070-2092)
- Aaron Seth Kesselheim (ORCID: https://orcid.org/0000-0002-8867-2666)
- Emanuel Krebs (ORCID: https://orcid.org/0000-0002-6590-8728)
- Ian Bosdet (ORCID: https://orcid.org/0000-0003-4739-007X)
- Aly Karsan (ORCID: https://orcid.org/0000-0001-6753-892X)
- Tania Bubela (ORCID: https://orcid.org/0000-0002-0807-2899)
Institutions
- Brigham and Women's Hospital (US)
- BC Cancer Agency (CA)
- University of British Columbia (CA)
- Fraser Health (CA)
- Simon Fraser University (CA)
- Spinal Cord Injury BC (CA)
- The Centre for Health (New Zealand) (NZ)
- BC Cancer Foundation (CA)
- Canada's Michael Smith Genome Sciences Centre (CA)
- Women's Health Research Institute (CA)
- Cancer Genetics (United States) (US)
Publication Details
- Journal
- JNCI Journal of the National Cancer Institute
- Published
- 2025-11-08
- DOI
- https://doi.org/10.1093/jnci/djaf307
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Genome Canada
- Genome British Columbia